oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Improving the management of high cost anticancer drugs in a health care system
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy.
School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy. (Nutrition Gut Brain Interactions)
Show others and affiliations
2016 (English)In: Global and Regional Health Technology Assessment, ISSN 2284-2403, Vol. 3, no 3, p. 155-158Article in journal (Other academic) Published
Abstract [en]

As a consequence of the rise in cancer prevalence and in the cost of anticancer drugs, global spending for cancer is increasing rapidly. The aim of this work is to identify and assess some effective cost management parameters and possible strategies to contain expenditure. Cost limitation could be achieved by implementing effective prevention measures and other main actions: diffusion of tailored therapies; systematic postmarketing reviews; cost-effectiveness assessment; accurate treatment choices; more transparent and effective managed entry agreement policies; waste management through personalized dose preparation. To better manage high cost anticancer drugs, oncologists and hospital pharmacists should collaborate in choosing the right drug, for the right patient, at the right time. In addition, besides promoting the use of biosimilars and generic drugs, when different products have a similar clinical effectiveness, a cost-minimization analysis should be performed to identify the best clinical approach at the lowest cost. With the same purpose, verifying real life outcomes by managing postmarketing analyses helps to renegotiate price agreements in a value-for-money model; this could be arranged if the regulatory agencies renegotiate the previously established price within a defined time period. Finally, the centralization of high-cost drug preparation and the implementation of a drug-day (vial sharing) will reduce drug waste.

Place, publisher, year, edition, pages
Milan, Italy: Wichtig Publishing , 2016. Vol. 3, no 3, p. 155-158
Keywords [en]
Drug expenditure, managed entry agreement, oncology, preparation waste, postmarketing register
National Category
Medical and Health Sciences Health Care Service and Management, Health Policy and Services and Health Economy
Research subject
Health and Medical Care Research; Economics
Identifiers
URN: urn:nbn:se:oru:diva-65210DOI: 10.5301/grhta.5000243ISI: 000405311400006OAI: oai:DiVA.org:oru-65210DiVA, id: diva2:1185426
Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2018-07-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Gorreja, Frida

Search in DiVA

By author/editor
Gorreja, Frida
Medical and Health SciencesHealth Care Service and Management, Health Policy and Services and Health Economy

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 32 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf